Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time. Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Without Ozempic's appetite-regulating effects, cravings for high-calorie, carbohydrate-rich foods may return. This can make ...
Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why ...
Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...
It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.
After screening 20,000 protein-encoding genes in the human body, Stanford researchers have identified a naturally occurring ...
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback